Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKinsey
Dow
Merck
Baxter
Colorcon
Mallinckrodt

Last Updated: December 12, 2019

DrugPatentWatch Database Preview

Baricitinib - Generic Drug Details

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What are the generic sources for baricitinib and what is the scope of patent protection?

Baricitinib is the generic ingredient in one branded drug marketed by Eli Lilly And Co and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Baricitinib has fifty-four patent family members in forty-two countries.

One supplier is listed for this compound.

Summary for baricitinib
International Patents:54
US Patents:2
Tradenames:1
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 82
Clinical Trials: 52
Patent Applications: 71
DailyMed Link:baricitinib at DailyMed
Recent Clinical Trials for baricitinib

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Washington University School of MedicinePhase 1
University Hospital, BrestPhase 2
Suzhou Zelgen Biopharmaceuticals Co.,LtdPhase 2

See all baricitinib clinical trials

Pharmacology for baricitinib
Synonyms for baricitinib
(1-(Ethylsulfonyl)-3-(4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)azetidin-3-yl)ethanenitrile
{1-(ethylsulfonyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]azetidin-3-yl}acetonitrile
1-(Ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]-3-azetidineacetonitrile
1187594-09-7
2-(3-(4-(3H-Pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(ethylsulfonyl)azetidin-3-yl)acetonitrile
2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(ethylsulfonyl)azetidin-3-yl)acetonitrile
2-[1-ETHYLSULFONYL-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PYRAZOL-1-YL]AZETIDIN-3-YL]ACETONITRILE
3-Azetidineacetonitrile, 1-(ethylsulfonyl)-3-(4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)-
3-AZETIDINEACETONITRILE, 1-(ETHYLSULFONYL)-3-[4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL]-
3JW
AB0035958
ABP001023
AC-27404
AJ-121247
AK143352
AKOS022186127
AKOS025401933
AM81232
AMMD00005
AOB87724
AX8261519
Baricitinib (INCB28050 LY3009104)
Baricitinib (JAN/USAN/INN)
Baricitinib (LY3009104, INCB028050)
Baricitinib (LY3009104)
Baricitinib [USAN:INN]
baricitinib-ly3009104
BC600315
BCP04686
BCP0726000031
BCP9000380
BDBM50021656
C16H17N7O2S
CHEBI:95341
CHEMBL2105759
CS-0724
D10308
DB11817
DS-7641
DTXSID30152228
EX-A413
GTPL7792
HMS3651L17
HY-15315
INCB 028050
INCB 28050
INCB-028050
INCB-028050|||LY-3009104|||2-[1-Ethylsulfonyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile
INCB028050
ISP4442I3Y
J-503551
KS-0000044L
LY 3009104
LY-3009104
LY3009104
MFCD21608464
MLS006011247
NCGC00345839-01
NCGC00345839-14
olumiant
Olumiant (TN)
PB27275
QCR-197
RL00725
S-7686
s2851
SB10845
SC-94301
SCHEMBL871150
SMR004703006
SW220096-1
UNII-ISP4442I3Y
XUZMWHLSFXCVMG-UHFFFAOYSA-N
Y0439
ZINC73069247

US Patents and Regulatory Information for baricitinib

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eli Lilly And Co OLUMIANT baricitinib TABLET;ORAL 207924-001 May 31, 2018 RX Yes Yes   Start Trial   Start Trial   Start Trial
Eli Lilly And Co OLUMIANT baricitinib TABLET;ORAL 207924-001 May 31, 2018 RX Yes Yes   Start Trial   Start Trial   Start Trial
Eli Lilly And Co OLUMIANT baricitinib TABLET;ORAL 207924-001 May 31, 2018 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for baricitinib

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2288610 1790035-8 Sweden   Start Trial PRODUCT NAME: BARICITINIB; REG. NO/DATE: EU/1/16/1170 20170215
2288610 PA2017023 Lithuania   Start Trial PRODUCT NAME: BARICITINIBAS IR FARMACINIU POZIURIU PRIIMTINOS JO DRUSKOS; REGISTRATION NO/DATE: EU/1/16/1170 20170213
2288610 2017C/025 Belgium   Start Trial PRODUCT NAME: OLUMIANT - BARICITINIB; AUTHORISATION NUMBER AND DATE: EU/1/16/1170 20170215
2288610 CA 2017 00032 Denmark   Start Trial PRODUCT NAME: BARICITINIB AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REG. NO/DATE: EU/1 /16/1170 20170215
2288610 PA2017023,C2288610 Lithuania   Start Trial PRODUCT NAME: BARICITINIBAS IR FARMACINIU POZIURIU PRIIMTINOS JO DRUSKOS; REGISTRATION NO/DATE: EU/1/16/1170 20170213
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
AstraZeneca
Baxter
McKesson
Boehringer Ingelheim
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.